Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) (clinicaltrials.gov) - Oct 10, 2026 - P1/2 | N=23 | Not yet recruiting | Sponsor: University of Utah | Initiation date: Aug 2026 ➔ Nov 2026
Trial initiation date • Hodgkin Lymphoma • Transplantation
|